Business Context and Reporting Period
This Form 8-K Current Report was filed by Anavex Life Sciences Corp. on October 1, 2015, with the earliest event reported on October 1, 2015. The filing primarily addresses a material modification to the rights of security holders via a reverse stock split and the appointment of a new Principal Financial Officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only quantitative financial metric disclosed is the compensation for the newly appointed Principal Financial Officer:
- Annual Base Salary: $78,000 CAD for Sandra Boenisch.
- Outstanding Shares (Pre-Split): 400,000,000 shares.
- Outstanding Shares (Post-Split): Approximately 100,000,000 shares.
Material Changes
Reverse Stock Split
The Board of Directors approved a 1-for-4 reverse stock split of the Company's common stock. Key details include:
- Effective Date: Anticipated to be October 6, 2015, at 4:30 p.m. Eastern Time, contingent upon FINRA approval.
- Ratio: Every four existing shares will be converted into one new share.
- Fractional Shares: Will be rounded up to the nearest whole share.
- Trading Symbol: Will temporarily trade under "AVXLD" for 20 business days before reverting to "AVXL".
- Adjustments: All outstanding options, warrants, and convertible securities will be adjusted accordingly.
Executive Appointment
Effective October 1, 2015, Sandra Boenisch was appointed as Principal Financial Officer. She holds a CPA (CGA) designation and has 14 years of experience in accounting and financial reporting. Her employment agreement runs through September 30, 2017, and includes a sign-on stock option grant.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future performance. The primary contingency noted is that the reverse stock split is not effective until the Company receives approval from the Financial Industry Regulatory Authority (FINRA). No other risks or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Confirm FINRA approval of the 1-for-4 reverse stock split to ensure the October 6, 2015 effective date is met.
- Verify the temporary trading symbol change to "AVXLD" and the subsequent reversion to "AVXL" after 20 business days.
- Check brokerage accounts for automatic adjustment of share counts and the issuance of new CUSIP numbers.
- Review the impact of the reverse split on the exercise price and number of shares for any outstanding options or warrants held.